![]() |
|
|
,3
Departments of
*
Human Biology and
Biochemistry, University of Maastricht, 6200 MD Maastricht and
**
Gaubius Laboratory, 2301 CE Leiden, The Netherlands
3To whom correspondence should be addressed. E-mail: JWM.Heemskerk{at}bioch.unimaas.nl.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: arterial disease coagulation fibrinolysis fish oil platelets
The interest in fish oil as a possible antithrombotic nutritional component arose in the mid-1970s with the observation that Greenland Inuits, consuming high amounts of fatty fish, had a tendency toward prolonged bleeding and a low incidence of cardiovascular disease. It was realized that fish and other marine oils are typically enriched in the (n-3) polyunsaturated fatty acids (PUFA),4 eicosapentaenoic acid, 20:5(n-3), and docosahexaenoic acid, 22:6(n-3). High consumption of (n-3) PUFA (>5 g daily) was thus considered to be responsible for the low incidence of arterial disease (1 ), although it later appeared that genetic factors also can be involved. Epidemiologic observations have pointed to a clear association between fish oil consumption and reduced risk of coronary heart disease, even with only two fish dishes per week (2 ). Early controlled intervention studies, e.g., with men who had recovered from myocardial infarction, also confirmed that regular intake of fatty fish or fish oil capsules reduced death from ischemic heart disease, although without clear effect on the incidence of reinfarction (3 ). Substantial research since has revealed a variety of changes in the hemostatic system that can explain the antithrombotic potential of fish oil. Surprisingly, however, when reviewing the literature, many described effects of fish oil intervention on surrogate in vitro end point measurements, such as hemostatic factors, are variable in outcome. This raises questions concerning the underlying causes and importance of the effect variation.
| Membrane Phospholipids, Platelets and Bleeding Time. |
|---|
|
|
|---|
As reviewed by others (4
,7
9
), many but not all human intervention studies indicate that fatty fish or fish oil intake reduces platelet activation.5 This effect is determined mainly as a reduced aggregation tendency of platelets (in vitro) or as a reduced production of the platelet secretion product ß-thromboglobulin (in vivo). It is primarily but not exclusively obtained under conditions in which production of thromboxane A2 is a rate-limiting step in the platelet-activation process. Typically, even at higher doses of (n-3) PUFA (
6 g/d), only about half of the reviewed studies described significant effects on platelet function. Accordingly, in spite of the firm evidence that dietary (n-3) PUFA modify the phospholipid fatty acid composition and alter the platelet eicosanoid metabolism, these modifications are not accompanied by proportionally reduced platelet activation (10
). Together, these data indicate that the antithrombotic potential of fish oil is unlikely to result only from diminished thromboxane A2 production by the platelets.
Some of the published studies reported a significant prolongation in the bleeding time after supplementation of (n-3) PUFA, whether in association with a reduced thromboxane formation or platelet function (4 ,11 ). A prolonged bleeding time is compatible with the antithrombotic potential of (n-3) PUFA. Combined administration of fish oil and aspirin resulted in a further prolongation of the bleeding time, whereas fish oil did not improve the aspirin-induced inhibition of platelet aggregation (12 ). This can be taken as another indication that fish oil and aspirin affect hemostasis via different mechanisms.
| Blood Lipids and Fibrinolysis. |
|---|
|
|
|---|
Few studies have been conducted to investigate whether fish oil has a positive, increasing effect on fibrinolysis. Particular attention has been paid to plasminogen activator inhibitor type 1 (PAI-1) activity. PAI-1 is a fibrinolysis inhibitor, which complexes with circulating tissue-type plasminogen activator and abolishes plasminogen activation and fibrin degradation. High PAI-1 levels are associated with increased risk of arterial disease either causally or as a marker. As reviewed elsewhere (16 ), few authors have reported that fish oil reduces PAI-1 activity, but the majority of the investigators showed significant increases in this factor. This increase, depending on the levels of other fibrinolysis variables, would point to a higher rather than an improved procoagulant state.
| Coagulation and Relation to Platelet Activation. |
|---|
|
|
|---|
The processes of platelet activation and coagulation are intimately linked and are mutually stimulatory (24 ). Activated platelets provide glycoproteins and a phosphatidylserine-containing outer membrane, the site at which coagulation factors assemble and become activated (Fig. 1 ). In the presence of phosphatidylserine-exposing membranes, thrombin formation in plasma is at least three times greater. Conversely, the thrombin that is generated is one of the most potent platelet agonists known. This positive interaction of platelet activation and coagulation can be quantified under physiologic conditions by measuring the generation and inactivation of thrombin in platelet-rich plasma (25 ). As indicated in Figure 2 , partial anticoagulant therapy with coumarin and partial platelet inhibition with aspirin have additive, suppressive effects on thrombin generation when measured with platelets and plasma. A similar, reduced and delayed generation of thrombin was also measured in plasma from healthy volunteers after a regular intake of (n-3) PUFA (Vanschoonbeek, K., unpublished data, 2002). Together, these data illustrate that, with fish oil, the combination of a moderate antiplatelet and anticoagulant effect is more thromboprotective than either effect alone (see Fig. 1 ).
|
|
Successful antiplatelet and anticoagulant therapies are often accompanied by an increased risk of bleeding. Fish and fish oil supplements, although generally well tolerated, have as their main adverse side effect a mild gastrointestinal discomfort, appearing as a fishy aftertaste, belching, nausea, flatulence or loose stools. Published fish oil intervention studies with healthy subjects do not provide indications for increased bleeding, even after a daily intake of
6 g (n-3) PUFA. Various papers explicitly mention the absence of easy bruising or clinical signs of (postoperative) bleeding after fish oil intake by patients with cardiovascular disease (26
28
). Positive interactions between (n-3) PUFA intake and oral anticoagulants have been noted, but these appear to occur in the absence of clinically relevant bleeding (29
). There is only an incidental report of a patient with minor nasal bleeding after a fish oil diet with concomitant anticoagulant therapy (30
). In another study, fatal coagulopathy occurred in a patient after abdominal aortic aneurysm resection, but here a causal relationship of fish oil supplementation and the bleeding diathesis was reported to be uncertain (31
). Only the Zutphen epidemiologic study, investigating the association between fish consumption and stroke incidence in the Netherlands, concluded that large amounts of seafood may increase hemorrhagic subtypes of stroke, whereas the consumption of only small amounts of fish reduce the incidence of ischemic stroke (32
). Vasodilation is another reported effect (usually advantageous) of (n-3) PUFA on the vascular system. However, a meta-analysis of clinical trials showed that the vasodilating effect was most pronounced in hypertensive patients and had little effect on healthy normotensive people (33
). Thus, from the current literature, there seems to be little reason to be concerned about disadvantageous effects, at least when fish oil is not combined with anticoagulant treatment.
Variable transcriptional regulation.
As indicated, the usually mild and diverse thrombosis-reducing effects of (n-3) PUFA intervention for platelets, plasma lipids and coagulation factors show high interstudy variation. Some fish oil effects, such as changes in triglycerides, fibrinogen and other factors, seem to be most prominent in patients with increased basal values. Even within studies, there is considerable variation in effects observed among individual subjects. Recent findings give an attractive explanation for the diverse and variable effects of (n-3) PUFA on hemostatic and lipid factors, i.e., influence on gene expression. Feeding fish oil to mice was found to down-regulate the hepatic mRNA level of sterol regulatory element-binding protein-1, which controls several lipogenic genes (34
). Also in mice, (n-3) PUFA suppress the endogenous peroxisome proliferator-activated receptor
(PPAR
), a ligand-activated transcription factor system (35
), whereas oxidized (n-3) PUFA activate PPAR
(36
). Genetic polymorphisms of (hemostatic) factors may be associated with a variable, subject-dependent response to PUFA of genes coding for apolipoproteins (37
). New research should indicate how important transcription factors and other regulatory elements are in mediating fish oil effects on the hemostatic system, e.g., regulation of hepatic secretion of triglycerides and (vitamin Kdependent) coagulation factors, and controlling the expression of platelet proteins. This can also reveal whether genetic components are involved in the subject-to-subject response variation to (n-3) PUFA, such as polymorphisms in one or more hemostatic genes.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
2 Manuscript received 4 October 2002. Initial review completed 23 October 2002. Revision accepted 19 December 2002. ![]()
4 Abbreviations used: COX1, cyclooxygenase-1; PAI-1, plasminogen activator inhibitor type 1; PPAR
, peroxisome proliferator-activated receptor
; PUFA, polyunsaturated fatty acids. ![]()
5 A table reviewing the fraction of published studies with a significant effect on this hemostatic variable is available as supplemental data in the online posting of this article at www.nutrition.org. ![]()
| LITERATURE CITED |
|---|
|
|
|---|
1. Bang, H. O., Dyerberg, J. & Nielsen, A. B. (1971) Plasma lipid and lipoprotein pattern in Greenlandic west-coast Eskimos. Lancet i:1143-1145.
2. Kromhout, D., Bosschieter, E. B. & de Coulander, C. L. (1987) The inverse relation between fish consumption and 2-year mortality from coronary heart disease. Lancet i:177-183.
3. Burr, M. L., Fehily, A. M., Gilbert, J. F., Rogers, S., Holliday, R. M., Sweetnam, P. M., Elwood, P. C. & Deadman, N. M. (1989) Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction; diet and reinfarction trial (DART). Lancet i:757-761.
4. Hornstra, G. (1989) The significance of fish and fish-oil enriched food for prevention and therapy of ischaemic cardiovascular disease. Vergroesen, E. G. eds. The Role of Fats in Human Nutrition 1989:152-235 Academic Press New York, NY. .
5. Needleman, P., Raz, A., Minkes, M. S., Ferrendelli, J. A. & Sprecher, H. (1979) Triene prostaglandins, prostacyclin and thromboxane biosynthesis and unique biological properties. Proc. Natl. Acad. Sci. U.S.A. 76:944-948.
6. Nieuwenhuys, C.M.A., Feijge, M.A.H., Offermans, R.F.G., Kester, A.D.M., Hornstra, G. & Heemskerk, J.W.M. (2001) Modulation of rat platelet activation by vessel wall-derived prostaglandin and platelet-derived thromboxane: effects of dietary fish oil on thromboxane-prostaglandin balance. Atherosclerosis 154:355-366.[Medline]
7. Kristensen, S. D., Schmidt, E. B. & Dyerberg, J. (1989) Dietary supplementation with n-3 polyunsaturated fatty acids and human platelet function: a review with particular emphasis on implications for cardiovascular disease. J. Intern. Med. 225:S141-S150.
8. Malle, E. & Kostner, G. M. (1993) Effects of fish oil on lipid variables and platelet function indices. Prostaglandins Leukot. Essent. Fatty Acids 49:645-663.[Medline]
9. Chin, J.P.F. (1994) Marine oils and cardiovascular reactivity. Prostagland. Leukot. Essent. Fatty Acids 50:211-222.[Medline]
10. Heemskerk, J.W.M., Vossen, C.R.M. & van Dam-Mieras, M.C.A. (1996) Polyunsaturated fatty acids and function of platelets and endothelial cells. Curr. Opin. Lipidol. 7:24-29.[Medline]
11. Thorngren, M., Shafi, S. & Born, G. V. (1984) Delay in primary haemostasis produced by a fish diet without change in local thromboxane A2. Br. J. Haematol. 58:567-578.[Medline]
12. Harris, W. S., Silveira, S. & Dujovne, C. A. (1990) The combined effects of n-3 fatty acids and aspirin on hemostatic parameters in man. Thromb. Res. 57:517-526.[Medline]
13. Harris, W. S. (1997) N-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 65:1645S-1654S.
14. Zucker, M. L., Bilyeu, D. S., Helmkamp, G. M., Harris, W. S. & Dujovne, C. A. (1988) Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis 73:13-22.[Medline]
15. Leaf, A. & Weber, P. C. (1988) Cardiovascular effects of n-3 fatty acids. N. Engl. J. Med. 318:549-557.[Medline]
16. Knapp, H. R. (1997) Dietary fatty acids in human thrombosis and hemostasis. Am. J. Clin. Nutr. 65:1687S-1698S.
17. Oosthuizen, W., Vorster, H. H., Jerling, J. C., Barnard, H. C., Smuts, C. M., Silvis, N., Kruger, A. & Venter, C. S. (1994) Both fish oil and olive oil lowered plasma fibrinogen in women with high baseline fibrinogen levels. Thromb. Haemost. 72:557-562.[Medline]
18. Shahar, E., Folsom, A. R., Wu, K. K., Dennis, B. H., Shimakawa, T., Conlan, M. G., Davis, C. E. & Williams, O. D. (1993) Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile. The atherosclerosis risk in communities (ARIC) study. Arterioscler. Thromb. 13:1205-1212.
19. Marckmann, P., Bladbjerg, E. M. & Jespersen, J. (1997) Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Arterioscler. Thromb. Vasc. Biol. 17:3384-3391.
20. Leray, C., Wiesel, M. L., Freund, M., Cazenave, J. P. & Gachet, C. (2001) Long-chain n-3 fatty acids specifically affect rat coagulation factors dependent on vitamin K. Arterioscler. Thromb. Vasc. Biol. 21:459-465.
21. Nieuwenhuys, C.M.A., Béguin, S., Offermans, R.F.G., Emeis, J. J., Hornstra, G. & Heemskerk, J.W.M. (1998) Hypocoagulant and lipid-lowering effects of dietary n-3 polyunsaturated fatty acids with unchanged platelet activation in rat. Arterioscler. Thromb. Vasc. Biol. 18:1480-1489.
22. Nieuwenhuys, C.M.A., Feijge, M.A.H., Vermeer, C., Hennissen, A.A.H. M., Béguin, S. & Heemskerk, J.W.M. (2001) Vitamin K-dependent and vitamin K-independent hypocoagulant effects of dietary fish oil in rats. Thromb. Res. 104:137-147.[Medline]
23. Haglund, O., Wallin, R., Luostarinen, R. & Saldeen, T. (1990) Effects of a new fluid fish oil concentrate, Eskimo-3, on triglycerides, cholesterol, fibrinogen and blood pressure. J. Intern. Med. 227:347-353.[Medline]
24. Heemskerk, J.W.M., Bevers, E. M. & Lindhout, T. (2002) Platelet activation and blood coagulation. Thromb. Haemost. 88:186-193.[Medline]
25. Hemker, H. C., Giesen, P.L.A., Ramjee, M., Wagenvoord, R. & Béguin, S. (2000) The thrombogram: monitoring thrombin generation in platelet rich plasma. Thromb. Haemost. 83:589-591.[Medline]
26. Wojenski, C. M., Silver, M. J. & Walker, J. (1991) Eicosapentaenoic acid ethyl ester as an antithrombotic agent: comparison to an extract of fish oil. Biochim. Biophys. Acta 1081:33-38.[Medline]
27. Roulet, M., Frascarolo, P., Pilet, M. & Chapuis, G. (1997) Effects of intravenously infused fish oil on platelet fatty acid phospholipid composition and on platelet function in postoperative trauma. J. Parenter. Enteral Nutr. 21:296-301.[Abstract]
28. De Caterina, R., Giannessi, D., Mazzone, A., Bernini, W., Lazzerini, G., Maffei, S., Cerri, M., Salvatore, L. & Weksler, B. (1990) Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 82:428-438.
29. Eritsland, J., Arnesen, H., Seljeflot, I. & Kierulf, P. (1995) Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul. Fibrinolysis 6:17-22.[Medline]
30. Smith, P., Arnesen, H., Opstad, T., Dahl, K. H. & Eritsland, J. (1989) Influence of highly concentrated n-3 fatty acids on serum lipids and hemostatic variables in survivors of myocardial infarction receiving either oral anticoagulants or matching placebo. Thromb. Res. 53:467-474.[Medline]
31. Bowles, M. H., Klonis, D., Plavac, T. G., Gonzales, B., Francisco, D. A., Roberts, R. W., Boxberger, G. R., Poliner, L. R. & Galichia, J. P. (1991) EPA in the prevention of restenosis post PTCA. Angiology 42:187-194.
32. Keli, S. O., Feskens, E. J. & Kromhout, D. (1994) Fish consumption and risk of stroke. The Zutphen study. Stroke 25:328-332.[Abstract]
33. Morris, M. C., Sacks, F. & Rosner, B. (1993) Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88:523-533.
34. Kim, H. J., Takahashi, M. & Ezaki, O. (1999) Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. J. Biol. Chem. 274:25892-25898.
35. Takahashi, M., Tsuboyama-Kasaoka, N., Nakatani, T., Ishii, M., Tsutsumi, S., Aburatani, H. & Ezaki, O. (2002) Fish oil feeding alters liver gene expressions to defend against PPAR
activation and ROS production. Am. J. Physiol. 282:G338-G348.
36. Sethi, S., Ziouzenkova, O., Ni, H., Wagner, D. D., Plutzky, J. & Mayadas, T. N. (2002) Oxidized
-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR
. Blood 100:1340-1346.
37. Wallace, A. J., Humphries, S. E., Fisher, R. M., Mann, J. I., Chisholm, A. & Sutherland, W.H.F. (2000) Genetic factors associated with response of LDL subfractions to change in the nature of dietary fat. Atherosclerosis 149:387-394.[Medline]
This article has been cited by other articles:
![]() |
C. T. Damsgaard, H. Frokiaer, A. D. Andersen, and L. Lauritzen Fish Oil in Combination with High or Low Intakes of Linoleic Acid Lowers Plasma Triacylglycerols but Does Not Affect Other Cardiovascular Risk Markers in Healthy Men J. Nutr., June 1, 2008; 138(6): 1061 - 1066. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Tepaske, H. te Velthuis, H. M. Oudemans-van Straaten, P. M. M. Bossuyt, M. J. Schultz, L. Eijsman, and M. Vroom Glycine Does Not Add to the Beneficial Effects of Perioperative Oral Immune-Enhancing Nutrition Supplements in High-Risk Cardiac Surgery Patients JPEN J Parenter Enteral Nutr, May 1, 2007; 31(3): 173 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
Do omega-3 fatty acids help in depression? DTB, February 1, 2007; 45(2): 9 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Vanschoonbeek, M. A. H. Feijge, W. H. M. Saris, M. P. M. de Maat, and J. W. M. Heemskerk Plasma Triacylglycerol and Coagulation Factor Concentrations Predict the Anticoagulant Effect of Dietary Fish Oil in Overweight Subjects J. Nutr., January 1, 2007; 137(1): 7 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Vanschoonbeek, M. A.H. Feijge, M. Paquay, J. Rosing, W. Saris, C. Kluft, P. L.A. Giesen, M. P.M. de Maat, and J. W.M. Heemskerk Variable Hypocoagulant Effect of Fish Oil Intake in Humans: Modulation of Fibrinogen Level and Thrombin Generation Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1734 - 1740. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Rock, S. W. Flatt, C. A. Thomson, M. L. Stefanick, V. A. Newman, L. Jones, L. Natarajan, J. P. Pierce, R. J. Chang, and J. L. Witztum Plasma Triacylglycerol and HDL Cholesterol Concentrations Confirm Self-Reported Changes in Carbohydrate and Fat Intakes in Women in a Diet Intervention Trial J. Nutr., February 1, 2004; 134(2): 342 - 347. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||